Ares Financial Consulting
ORKA icon

Ares Financial Consulting’s Oruka Therapeutics ORKA Stock Holding History

Ares Financial Consulting’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-7
Closed -$666 – 1144
2026
Q2 		$666 Buy
+7
New +$466 ﹤0.01% 1062

Other funds holding ORKA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
SEB Asset Management
SEB Asset Management Stockholm $27B AUM
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Ares Financial Consulting's ORKA Position: Q3 2026 in Review

Ares Financial Consulting sold out of Oruka Therapeutics (ORKA) in Q3 2026, closing a stake of 7 shares — an estimated $666 sold.

Ares Financial Consulting first reported a position in ORKA in Q2 2026 and held it in 1 quarter. The position peaked at $666 in Q2 2026. 78 funds tracked by Wall St. Rank hold ORKA as of Q3 2026.

  • Ares Financial Consulting reported no remaining Oruka Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Ares Financial Consulting sold 7 Oruka Therapeutics shares in Q3 2026, an estimated $666.
  • Ares Financial Consulting first reported a position in Oruka Therapeutics in Q2 2026 and held it in 1 quarter.
  • Ares Financial Consulting's Oruka Therapeutics position peaked at $666 in Q2 2026.
  • 78 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q3 2026.

Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.